• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Amryt Signs Four New Lojuxta Deals in the Middle East

Article

UK-based Amryt, a biopharmaceutical company focused on rare and orphan diseases, has announced the signing of four further distribution agreements for its Homozygous Familial Hypercholesterolaemia (HoFH) treatment, Lojuxta, across the Middle East. The agreements have been signed with Al Hafez Trading Establishment (Kuwait), Ebn Sina Medical (Qatar), Muscat Pharmacy and Stores (Oman), and Goro Healthcare (UAE/Bahrain).    Amryt has signed nine distribution agreements for Lojuxta since November 2017. On the latest deals, Joe Wiley, the company's CEO, commented: “The Middle East has a higher HoFH patient population per capita than Europe and we look forward to working closely with our new distribution partners to improve patient outcomes.”    An interview with Amryt's Dr. Joe Wiley will feature in the upcoming June issue of Pharmaceutical Executive.

Recent Videos
Related Content